Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer

British Journal of Cancer

Volumn 82, Issue 4, 2000, Pages 812-817

  Eisen, T ^a,c   Boshoff, C ^a,c   Mak, I ^b   Sapunar, F ^a   Vaughan, M M ^a   Pyle, L ^a   Johnston, S R D ^a   Ahern, R ^a   Smith, I E ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Renal cell carcinoma; Thalidomide; TNF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ADVANCED CANCER; APPETITE; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CONSTIPATION; EDEMA; FEMALE; HEADACHE; HUMAN; KIDNEY CANCER; LETHARGY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SLEEP; URINE LEVEL;

EID: 0033980850     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1004     Document Type: Article

References (38)

1. Asscher W (1994) Safety of Thalidomide. Br Med J 309: 193-194 (letter)
2. Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73: 333-346
3. Boshoff C and Jones AL (1996) Tumour necrosis factor. In: Immunotherapy in Cancer, Gore ME and Riches P (eds), pp. 77-103. John Wiley: London
4. Burrows FJ and Thorpe PE (1994) Vascular targeting - a new approach to the therapy of solid tumours. Pharmacol Ther 64: 155-174
5. Bussolino F, Albini A, Camussi G, Presta M, Vigliotto G, Ziche M and Persico G (1996) Role of soluble mediators in angiogenesis. Eur J Cancer (Special issue: basic and clinical research on angiogenesis) 32A: 2401-2412
6. Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR and Baguley BC (1995) Effect of Thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxantheone-4-acetic acid. Br J Cancer 72: 339-343
7. Crawford CL (1994) Use of Thalidomide in leprosy. Adverse Drug React Toxicol Rev 13: 177-192
8. D'Amato RJ, Loughnan MS, Flynn E and Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085
9. Eisenbud L, Horowitz I and Kay B (1987) Recurrent aphthous stomatitis of the Behçet's type: successful treatment with Thalidomide. Oral Surg Oral Med Oral Pathol 64: 289-292
10. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ and de Waal RM (1997) Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res Suppl 2: S19-26
11. Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC (1992) Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 140: 539-544
12. Folkman J (1995a) Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1: 27-31
13. Folkman J (1995b) Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763
14. Fullerton PM and Kremer M (1961) Neuropathy after intake of Thalidomide (Distaval). Br Med J 2: 853-858
15. Gasparini G (1996) Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A: 2485-2493
16. Hamada J, Cavanaugh PG, Lotan O and Nicolson GL (1992) Separable growth and migration factors for large cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 66: 349-354
17. Haslett PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25: 53-57
18. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamuru T, Brem H and Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557
19. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ and Wohl DA (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl Med 336: 1487-1493
20. Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL, de Kernion JB and Belldegrum A (1992) Interleukin-6 and renal cell cancer: production, regulation and growth effects. Cancer Immunol Immunother 35: 97-105
21. Lenz W (1962) Thalidomide and congenital abnormalities. Lancet 1: 45 (letter)
22. Lopez-Hanninen E, Kirchner H and Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25
23. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2: 1358 (letter)
24. Millar AB, Hoogstraten B and Staquet M (1981) Reporting results of cancer treatment. Cancer 47: 207-214
25. Mizutani Y, Bonavida B, Nio Y and Yoshida O (1994) Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha downregulation in tumor cell sensitization. J Urol 151: 1697-1702
26. Parman T, Wiley MJ and Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of Thalidomide teratogenicity. Nat Med 5: 582-585
27. Powell RJ and Gardner-Medwin JM (1994) Guideline for the clinical use and dispensing of Thalidomide. Postgrad Med J 70: 901-904
28. Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E and Neeman M (1997) Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 94: 13203-13208
29. Talbot DC and Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A: 2528-2533
30. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W and Kaplam G (1995) Thalidomide treatment reduces tumour necrosis alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1: 384-397
31. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ and Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586
32. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM and Wingard JR (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326: 1055-1058
33. Weidmann E, Bergmann L, Stock J, Kirsten R and Mitrou PS (1992) Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother 12: 123-131
34. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19
35. Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumor angiogenesis and metastasis - correlation in invasive breast cancer. N Engl J Med 324: 1-8
36. Wettstein AR and Meagher AP (1997) Thalidomide in Crohn's disease. Lancet 350: 1445-1446 (letter)
37. Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R and Mundy GR (1991) Evidence that tumour necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcaemia, and leukocytosis in a human tumour in nude mice. J Clin Invest 87: 977-985
38. Ziegler J (1996) Angiogenesis research enjoys growth spurt in the 1990s. J Natl Cancer Inst 88: 786-788